Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RestorAATion-2
NCT06405633Phase 2Recruiting
- Sponsor
- Wave Life Sciences
- Start
- Jul 2024
- Primary completion
- Sep 2027
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 6
01
Overview
Phase 2, open-label trial of WVE-006 in alpha-1 antitrypsin deficiency (AATD) (5 arms), sponsored by Wave Life Sciences. Primary endpoint: Adverse Events at 36 weeks. Started Jul 2024; status: recruiting.
02
Drugs
WVE-006
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT06405633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06405633.